Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Trial of SGLT2 Inhibition With Empagliflozin in Adults With Fontan Circulatory Failure (EMPA-HEART 3 CardioLink-12)

NCT06955260 is registered in ClinicalTrials.gov with Subodh Verma as lead sponsor.

NCT NCT06955260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06955260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Trial of SGLT2 Inhibition With Empagliflozin in Adults With Fontan Circulatory Failure (EMPA-HEART 3 CardioLink-12)
Lead sponsor
Subodh Verma
Phase
Phase 3
Overall status
Recruiting
Start date
May 29, 2026
Completion date
March 31, 2028
Enrollment
410 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

congenital heart disease